<SEC-DOCUMENT>0000950170-25-055884.txt : 20250418
<SEC-HEADER>0000950170-25-055884.hdr.sgml : 20250418
<ACCEPTANCE-DATETIME>20250418163118
ACCESSION NUMBER:		0000950170-25-055884
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250418
DATE AS OF CHANGE:		20250418

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PLUS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001095981
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				330827593
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-280061
		FILM NUMBER:		25850682

	BUSINESS ADDRESS:	
		STREET 1:		4200 MARATHON BLVD.
		STREET 2:		SUITE 200
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78756
		BUSINESS PHONE:		737.255.7194

	MAIL ADDRESS:	
		STREET 1:		4200 MARATHON BLVD.
		STREET 2:		SUITE 200
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78756

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTORI THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20050712

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MACROPORE INC
		DATE OF NAME CHANGE:	20010320
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>4-18-25_8-k_424b3.htm
<DESCRIPTION>424B3
<TEXT>
<html>
 <head>
  <title>424B3</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Filed Pursuant to Rule 424(b)(3)<br>Registration No. 333-280061</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PROSPECTUS SUPPLEMENT NO. 9</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(To Prospectus dated June 24, 2024)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img265656815_0.jpg" alt="img265656815_0.jpg" style="width:159px;height:91px;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plus Therapeutics, Inc.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This prospectus supplement updates and supplements the prospectus, dated June 24, 2024 (as supplemented to date, the &#x201c;Prospectus&#x201d;), which forms a part of our registration statement on Form S-1 (</font><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No. 333-280061</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). This prospectus supplement is being filed to update and supplement the information in the Prospectus with the information contained in our Current Report on Form  filed with the Securities and Exchange Commission on April 18, 2025 (the &#x201c;Current Report&#x201d;). Accordingly, we have attached the Form  to this prospectus supplement.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock, par value $0.001 per share (&#x201c;Common Stock&#x201d;) is listed on The Nasdaq Capital Market LLC under the symbol &#x201c;PSTV&#x201d;. On April 17, 2025, the closing price of our Common Stock was $0.66.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a &#x201c;smaller reporting company&#x201d; for purposes of federal securities laws and are subject to reduced public company reporting requirements. Accordingly, the information in the Prospectus and this prospectus supplement may not be comparable to information provided by companies that are not smaller reporting companies.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business and investment in our Common Stock involve significant risks. These risks are described in the section titled &#x201c;Risk Factors&#x201d; beginning on page 13 of the Prospectus, and under similar headings in any amendments or supplements to the Prospectus.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense.</font></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The date of this prospectus supplement is April 18, 2025</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Form 8-K</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Current Report</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Exchange Act of 1934</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date of Report</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Date of earliest event reported)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: April 18, 2025</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PLUS THERAPEUTICS, INC.<br> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of registrant as specified in its charter)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:89.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:33.333%;box-sizing:content-box;"></td>
     <td style="width:33.333%;box-sizing:content-box;"></td>
     <td style="width:33.333%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-kerning:none;min-width:fit-content;">Delaware</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(State or other jurisdiction<br>of incorporation)</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">001-34375</font></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Commission File Number)</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">33-0827593</font></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(IRS Employer<br>Identification No.)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:48.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2710 Reed Road, Suite 160, Houston, Texas 77051</font></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Address of principal executive offices, with zip code)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(737) 255-7194</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Registrant&#x2019;s telephone number, including area code)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">N/A</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former name or former address, if changed since last report)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="border-top:1pt solid #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&uml;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&uml;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&uml;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&uml;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:<br><br></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:93.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:38.568%;box-sizing:content-box;"></td>
     <td style="width:20.884%;box-sizing:content-box;"></td>
     <td style="width:40.548%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading Symbol(s)</font></p></td>
     <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, par value $0.001</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PSTV</font></p></td>
     <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Capital Market</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#x2009;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#x2009;240.12b-2 of this chapter).</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&uml;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;">&uml;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Wingdings',serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="border-top:1pt solid #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5.02 	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Appointment to Board of Directors</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 18, 2025, the Board of Directors (the &#x201c;Board&#x201d;) of Plus Therapeutics, Inc (the &#x201c;Company&#x201d;) unanimously appointed Mr. Kyle Guse to serve as a director of the Board, effective immediately. Mr. Guse is being appointed to the Board to fill the vacancy created by the resignation of Mr. Greg Petersen, and is expected to stand for reelection at the Company&#x2019;s next annual meeting of stockholders.  The Board has determined that Mr. Guse satisfies the definition of an &#x201c;independent director&#x201d; under the Nasdaq listing standards and the Company&#x2019;s Corporate Governance Guidelines. Mr. Guse was also appointed to the Audit Committee and Compensation Committee of the Board and as Chairman of the Audit Committee.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mr. Guse currently serves as the Chief Legal Officer of DDC Enterprise Ltd., an NYSE-American-listed international consumer foods company, a position he has held since September 2023. From January 2013 to May 2023, Mr. Guse was Chief Financial Officer, General Counsel and Secretary of Atossa Therapeutics, Inc., a Nasdaq-listed biotechnology company developing treatments and prevention for breast cancer. Mr. Guse&#x2019;s experience includes 30 years of counseling innovative, rapid growth companies through all aspects of finance, corporate governance, securities laws and commercialization, with a particular focus on mergers and acquisitions and capital markets transactions. Mr. Guse has practiced law at several of the largest international law firms, including from January 2012 through January 2013 as a partner at Baker Botts LLP and, prior to that, from October 2007 to January 2012, as a partner at McDermott Will &amp; Emery LLP. Before working at McDermott Will &amp; Emery, Mr. Guse served as a partner at Heller Ehrman LLP. Mr. Guse began his career as an accountant at Deloitte and he is an inactive Certified Public Accountant and member of the Bars in California and Washington. Mr. Guse earned a B.S. in business administration and an M.B.A. from California State University, Sacramento, and a J.D. from Santa Clara University School of Law.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mr. Guse will be eligible to receive compensation for his service on the Board and its committees consistent with that provided to all non-employee directors for such service, which is described under the caption &#x201c;Director Compensation&#x201d; in the Company&#x2019;s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on July 10, 2024, as adjusted by the Board from time to time.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There was no arrangement or understanding between Mr. Guse and any other person with respect to his appointment to the Board. In addition, there have been no transactions involving Mr. Guse that would be required to be disclosed pursuant to Item 404(a) of Regulation S-K.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with his appointment, Mr. Guse is expected to execute the Company&#x2019;s standard form of indemnification agreement for directors, a copy of which was filed as Exhibit 10.1 to the Company&#x2019;s Current Report on Form 8-K filed with the SEC on February 6, 2020.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Resignation from Board of Directors</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 18, 2025, Mr. Greg Petersen resigned as a member of the Board. Mr. Petersen informed the Company that his resignation was not the result of any disagreement with the Company on any matter relating to the Company&#x2019;s operations, policies or practices.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.667%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date: April 18, 2025</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:18.333%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PLUS THERAPEUTICS, INC.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:50.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:11.54%;box-sizing:content-box;"></td>
     <td style="width:88.46%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;By:</font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Marc H. Hedrick, M.D.</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marc H. Hedrick, M.D.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>img265656815_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img265656815_0.jpg
M_]C_VP!#  0# P0# P0$ P0%! 0%!@H'!@8&!@T)"@@*#PT0$ \-#PX1$Q@4
M$1(7$@X/%1P5%QD9&QL;$!0='QT:'Q@:&QK_VP!# 00%!08%!@P'!PP:$0\1
M&AH:&AH:&AH:&AH:&AH:&AH:&AH:&AH:&AH:&AH:&AH:&AH:&AH:&AH:&AH:
M&AH:&AK_P  1" !^ -P# 2(  A$! Q$!_\0 '0 !  ,! 0$! 0$
M  8'" 0%"0(# ?_$ $T0  $#! $" P0#"0P'"0    $" P0 !081!Q(A"!,Q
M%")!46%ULQ48,C8W<8&ATR,U0E)58G21DI2RQ!96<H*5HK$D,W.#EK3!U.'_
MQ  : 0$  @,!                 P4!! 8"_\0 ,Q$  0,# 04$"@(#
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M@ZZ4GY]S\!4LQ_+LP3QY?[_G-@M5JNUO;E/1HD&YF6R\TTUU)*G0D:)6%I(
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M&90OOL62)F,W@+;Z6VD1V_=0E*SU^\ .P_A)&]=UAV W<*4I7D]"E*4 I2E
M*4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4
J I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
